

**SONY**

Want to see all  
the colors?

*The choice is black  
and silver.*



FP7000 Spectral Cell Sorter

ID7000™ Spectral Cell Analyzer

## *The Journal of* **Immunology**

REVIEW ARTICLE | FEBRUARY 01 2017

### Targeting Metabolism as a Novel Therapeutic Approach to Autoimmunity, Inflammation, and Transplantation **FREE**

Ian A. Bettencourt; ... et. al

*J Immunol* (2017) 198 (3): 999–1005.

<https://doi.org/10.4049/jimmunol.1601318>

#### **Related Content**

Regulation of T cell activation and pathogenicity by dimeric pyruvate kinase M2 (PKM2)

*J Immunol* (May,2019)

Metabolic Reprogramming Is Required for Antibody Production That Is Suppressed in Anergic but Exaggerated in Chronically BAFF-Exposed B Cells

*J Immunol* (April,2014)

## Targeting Metabolism as a Novel Therapeutic Approach to Autoimmunity, Inflammation, and Transplantation

Ian A. Bettencourt and Jonathan D. Powell

Immune cell activation and differentiation occurs concurrently with metabolic reprogramming. This ensures that activated cells generate the energy and substrates necessary to perform their specified function. Likewise, the metabolic programs among different cells of the immune system vary. By targeting different metabolic pathways, these differences allow for selective regulation of immune responses. Further, the relative susceptibility of cells to a metabolic inhibitor is dictated by their metabolic demands; cellular selectivity is based on demand. Therefore, where differences exist in metabolic pathways between healthy and pathogenic cells, there is opportunity for selective regulation with agents lacking intrinsic specificity. There are now a host of studies demonstrating how inhibitors of metabolism (e.g., glycolysis, glutamine metabolism, and fatty acid oxidation) can regulate immune responses and treat immune-mediated pathogenesis. In this brief review we detail how inhibitors of metabolism can be employed to regulate immune responses in both autoimmunity and transplantation. *The Journal of Immunology*, 2017, 198: 999–1005.

In the past decade, the field of immunology has been characterized by a marked increase in our understanding of genetic and signaling programs that define immune cells. More recently, it has become clear that a key component of immune cell regulation and function is the concomitant reprogramming of metabolic pathways (1). The metabolism of a naive lymphocyte is different from that of a memory cell and is different from that of an effector (and indeed, even effector subsets have great differences in their metabolic profiles) (2). These differences offer promising opportunities for selective regulation of immune subsets. Furthermore, recent studies suggest that even metabolic inhibitors that lack intrinsic specificity can be made to affect only a select subset of cells based on the metabolic demands of those cells. This principle of cellular selectivity based upon cellular demand underlies a great deal of metabolic therapy and is broadly applicable to a number of different cells and disease types.

The particular metabolism of lymphocytes differs at each stage of development and has been extensively detailed elsewhere (2–5). In brief, naive lymphocytes resemble many of the somatic cells in the body and progress through metabolic pathways in a textbook fashion, relying on glycolysis and subsequent TCA cycling to produce a maximum amount of ATP (2). However, upon activation, there is a dramatic shift in the metabolism of lymphocytes. Similar to the Warburg effect, which was first observed by the biochemist Otto Warburg in cancer cells (6), there is a tremendous increase in glycolysis, even in the presence of abundant oxygen (7). This aerobic glycolysis seems counterintuitive but is actually a metabolic program undertaken by the cell that prioritizes the early generation of biosynthetic intermediates, which are necessary for activation, proliferation, and effector function. This metabolic change is facilitated by the upregulation of several key transporters, enzymes, and signaling pathways (8, 9). Effector cells also have differences in their metabolism between different subsets, with Th1, Th2, and Th17 tending to be more glycolytic, whereas regulatory T cells (Tregs) rely more on lipid metabolism (8). These subset differences provide another opportunity for differential regulation, based on the select needs of the particular subset. Different effector subsets also have different signaling pathways, such as differential mTOR complex I or II requirements for Th1/Th17 or Th2 cells (10, 11), or increased AMP kinase (AMPK) activation in Tregs (8), further expanding the potential for selective manipulation of cellular processes based upon their differential metabolic demands.

The transition from effector cell to memory cell involves further metabolic changes. Memory cells are more reliant on fatty acid oxidation and have increased mitochondrial mass (12, 13). This increase in mitochondria is coupled with the increase in spare respiratory capacity (13). From a metabolic perspective, memory cells are fueled to last. Furthermore, these metabolic changes allow the memory T cell to rapidly expand and to take on an effector function upon restimulation (14). From this overview of naive, effector, and memory T cell metabolism, a picture emerges whereby selectively regulating metabolic pathways can lead to the fine-tuned

Department of Oncology, Bloomberg-Kimmel Institute for Cancer Immunotherapy, The Sidney-Kimmel Comprehensive Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231

Received for publication August 2, 2016. Accepted for publication September 20, 2016.

This work was supported by National Institutes of Health Grants AI072677, AI77610, and AI09148.

Address correspondence and reprint requests to Dr. Jonathan D. Powell, Johns Hopkins University School of Medicine, CRB1 Room 443, 1650 Orleans Street, Baltimore, MD 21231. E-mail address: poweljo@jhmi.edu

Abbreviations used in this article: AMPK, AMP kinase; BMT, bone marrow transplantation; DC, dendritic cell; DCA, dichloroacetate; 2DG, 2-deoxy-glucose; DON, 6-diazo-5-oxo-L-norleucine; GVHD, graft-versus-host disease; PDH, pyruvate dehydrogenase; PDHK, PDH kinase; PKM2, pyruvate kinase M2; ROS, reactive oxygen species; SLE, systemic lupus erythematosus; Treg, regulatory T cell.

Copyright © 2017 by The American Association of Immunologists, Inc. 0022-1767/17/\$30.00

regulation of immune function. In this brief review, we will highlight several instructive examples of how the differential metabolism of innate and adaptive immune cells is beginning to be exploited therapeutically.

*Targeting signaling by targeting metabolites in innate and adaptive immune cells*

The shift in the metabolism of innate immune cells upon activation is similar yet distinct from that which occurs in the adaptive immune system (2, 15). This is advantageous, because it provides opportunities for both concurrent and differential regulation of the two arms of the immune response. Upon activation of macrophages and dendritic cells (DCs) in an inflammatory context, there is a shift from the quiescent state to a Warburg phenotype that is similar to that of activated lymphocytes (16, 17). This is accompanied by a decrease in the flux through the TCA cycle (18, 19). However, the goal of this shift in metabolism is not to support proliferation. Rather, such metabolic changes support full activation and cytokine production (20), as well as other important host defense functions, such as phagocytosis (21). DCs require a shift to aerobic glycolysis to mature and become capable of presenting Ag and activating lymphocytes (17, 18, 22). When hexokinase, an enzyme involved in the first step of glycolysis, is inhibited by treatment with the small molecule inhibitor 2-deoxy-glucose (2DG), macrophages stimulated with LPS display mitigated production of IL-1 $\beta$  (19, 23). Underlining the specificity of this metabolic approach, targeting hexokinase with 2DG can selectively block IL-1 $\beta$  production whereas not altering the transcription of TNF- $\alpha$  (19).

In addition to the shift to aerobic glycolysis, innate cells undergo a number of other metabolic changes, which are potential targets for metabolic therapies. The manipulation of these metabolites takes on an added importance because many metabolites also function as signaling molecules, the alteration of which can have profound effects on the downstream immune response. In this context, metabolites are not simply the end product of metabolism, but also can alter cell function by differentially signaling separate biochemical and molecular pathways.

The production of NO is sustained by the increased glycolysis after activation (24) and is required for activation-induced inhibition of oxidative phosphorylation (25). In addition, reactive oxygen species (ROS) are associated with priming the NLRP3 inflammasome (26). Treatment with metformin, a diabetes drug that activates AMPK (27), can decrease the production of ROS as a mechanism for modulating immune responses (28). ROS are also key for T cell activation, because lymphocytes that are genetically incapable of producing mitochondrial ROS cannot activate NFAT translocation to the nucleus or produce IL-2 (29). Another metabolite in flux is citrate, which is pumped out of the mitochondria and can serve as a substrate for histone acetylation, and thereby facilitate the epigenetic activation of genes crucial to metabolic pathways (30, 31). Histone acetylation has recently been shown to be important in the IL-4-induced polarization of M2 macrophages and is tightly controlled by ATP citrate lyase (32). Cytoplasmic citrate can also be used as a substrate for lipid biogenesis and the production of ROS or NO (33).

Another metabolite that increases upon stimulation is succinate. The increase in glutamine metabolism that accompanies aerobic glycolysis paradoxically increases the succinate present in macrophages after stimulation, even though flux through the TCA cycle is decreased (18). Succinate stabilizes HIF-1 $\alpha$ , which leads to increased production of IL-1 $\beta$ . Inhibition of glycolysis with 2DG prevents this increase in succinate upon stimulation and leads to a decrease in IL-1 $\beta$  production, as detailed later (19). Recently, an important role for itaconate in regulating macrophage inflammation has been demonstrated (34). Itaconate has a regulatory role in macrophage metabolism and acts by competitive inhibition of succinate dehydrogenase (35). In this model, itaconate endogenously produced by *Irg1* has been shown to inhibit succinate dehydrogenase, which leads to a block in the TCA cycle and a subsequent increase in succinate accumulation in LPS-stimulated macrophages. Alternatively, in IRG1<sup>-/-</sup> cells there is an increase in HIF-1 $\alpha$  concurrent with a relative decrease in succinate (34). Such findings demonstrate an additional link of the HIF-1 $\alpha$ -IL-1 $\beta$  axis to the efficiency and directionality of the electron transport chain.

Acetate also plays a role in guiding cellular differentiation and function. Acetate is increased systemically upon bacterial infection (36). When memory CD8 T cells that were initially primed in increased acetate are restimulated, they are able to mount a more rapid response and have a more dramatic increase in glycolysis upon restimulation. In addition, adoptive transfer of CD8 memory cells that were initially simulated in acetate is more protective against *Listeria* challenge (36).

Facilitating the metabolic shift that occurs upon activation, cells of the innate immune system undergo transcriptional and signaling pathway changes that dramatically alter their behavior. One such transcriptional change (that was mentioned earlier) is an increase in HIF-1 $\alpha$  upon the induction of aerobic glycolysis. This increase in HIF-1 $\alpha$  occurs under normal oxygen tension, is promoted by mTOR signaling, and is necessary for cytokine production upon activation (19, 37). Corresponding to the increased mTOR signaling after activation, there is a decrease in AMPK signaling in innate immune cells upon LPS stimulation. However, metformin treatment activates the AMPK signaling pathway, and this activation is sufficient to decrease IL-1 $\beta$  production, as well as increase the production of IL-10 (28). In addition to activating AMPK, metformin also inhibits electron transport chain complex I (38). Interestingly, the ability of metformin to promote a shift to a more immunosuppressive cytokine profile is also found in rotenone, which also inhibits electron transport chain complex I (28).

As is the case for the various subsets of effector T cells, M1 and M2 macrophages also have different metabolic demands. Transcriptional differences between the classically defined M1 and M2 cells also have important metabolic consequences. The alternatively activated M2 macrophages have a metabolism somewhat similar to Tregs with oxidative phosphorylation providing their energy, as opposed to aerobic glycolysis (39). In addition, M2 macrophages have less inducible NO synthase expression (leading to decreased NO production), increased AMPK activity, and less HIF-1 $\alpha$  (15). Further, it has been proposed that an IL-4-mediated increase in PGC-1 $\beta$  is the driver of the oxidative phosphorylation that characterizes the metabolism of M2 macrophages (39). This metabolic and

signaling phenotype is in contrast with the metabolic changes that occur in more proinflammatory innate immune cells, and provides potential differences with which the balance between macrophage subtypes can be manipulated.

Parallel analysis of transcriptional and metabolomics data has provided further insight into the metabolic circuitry of activated macrophages. Using a combined metabolic and transcriptional analysis, termed CoMBI-T, Jha and colleagues (40) were able to simultaneously examine the interplay between metabolites and the enzymes involved in pathways that use or generate them. This approach revealed strikingly different metabolic profiles in M1 and M2 macrophages. In the M1 macrophages, the conversion of isocitrate to  $\alpha$ -ketoglutarate was specifically found to be deficient, because of decreased transcription of the enzyme responsible for that reaction, isocitrate dehydrogenase (*Idh1*). Decreased  $\alpha$ -ketoglutarate production in M1 macrophages requires that citric acid serve as a precursor for itaconate and fatty acid synthesis (40). *Irg1*, as discussed earlier, is one of the most strongly upregulated transcripts in M1 macrophages as identified by CoMBI-T analysis, thus leading to increased levels of itaconate in M1-activated macrophages. Dimethyl itaconate administration was able to partially reverse tissue injury in a cardiac ischemia-reperfusion model, in which damage is caused in part by hypoxia-induced ROS production (41). Dimethyl itaconate pretreatment was also shown to decrease ROS production in bone marrow-derived macrophages, as well diminish inflammatory cytokine production and inflammatory activation (34). In contrast, M2 macrophages require glutamine metabolism. The generation of UDP-GlcNAc was found to be highly dependent on glutamine, because labeled nitrogen from glutamine made up more than half of the nitrogen in UDP-GlcNAc after just 4 h. Glutamine deprivation dramatically decreased M2 generation, leading to downregulation specifically in M2 signature gene transcription. This includes downregulation of *CCL22*, the secretion of which was also dramatically reduced in glutamine-free media (40). However, glutamine concentration had no impact on M1 polarization as measured by inducible NO synthase expression (40). Furthermore, it has been shown that glutamine deficiency actually increases the production of TNF- $\alpha$ , while protecting LPS-stimulated macrophages from lipid toxicity (42).


In addition to metabolites altering macrophage polarization, enzymatic differences can shift the balance between M1 and M2 macrophages. Pyruvate kinase M2 (PKM2) is transcriptionally upregulated upon LPS stimulation of bone marrow-derived macrophages and can form a dimer that is enzymatically inactive, but can travel to the nucleus and induce transcription of glycolytic genes by interacting with HIF-1 $\alpha$  (43). Small molecules DASA-58 and TEPP-46 force PKM2 into a tetrameric conformation (44), which is incapable of promoting HIF-1 $\alpha$  transcription, leading to a decrease in IL-1 $\beta$  production after LPS stimulation (45). Furthermore, treatment with TEPP-46 decreases M1 macrophage polarization after LPS stimulation, and both DASA-58 and TEPP-46 dramatically decrease activation-induced glycolysis. TEPP-46 administration leads to decreased IL-1 $\beta$  production and increased bacterial loads in the spleen and liver of mice infected with *Salmonella typhimurium*, because of decreased cellular killing of bacteria (45). Although deleterious in this case, the

possibility exists that these small molecules that prevent the activity of PKM2 could be beneficial in treating autoimmune inflammatory diseases. Although there has been less focus on the intervention of innate immune metabolism in treating autoimmunity and destructive inflammation, this is a field ripe for further exploration.

#### *Targeting metabolism in bone marrow transplantation*

In addition to their role in protective immunity, T lymphocytes make an important contribution to disease pathogenesis in a variety of autoimmune conditions. Normally, T cell metabolism, upon activation, involves a rapid increase in aerobic glycolysis (along with a concurrent transcriptional/translational increase in the machinery involved in these processes) and an increase in the uptake of glutamine to replenish the TCA cycle to derive anaplerotic substrates from that pathway (2). Also, activated T cells display increased shunting of carbons into alternative metabolic circuits, such as the pentose phosphate pathway (46). However, in a number of autoimmune diseases, this metabolism is disrupted. In the case of graft-versus-host disease (GVHD) after bone marrow transplantation (BMT), T cell metabolism is remarkably shifted. The immune response in GVHD is characterized by a constant encounter between the activated lymphocytes and their target tissue. This constant, high level of Ag engagement appears to lead to a different metabolism in the pathogenic donor cells. Their high requirement for ATP means they cannot subsist on oxidative glycolysis alone, and therefore such cells are forced to find an alternate source of fuel. This can be provided by the oxidation of fatty acids (47). When examining the metabolic tracing of  $^{13}\text{C}$ -labeled glutamine, glucose, and palmitate in T cells from a mouse model of GVHD after allotransplant, it was found that glutamine uptake and incorporation into RNA (as ribose) and fatty acids (as palmitate) are markedly increased as compared with T cells from naive mice. This is in contrast with the results of labeled glucose tracer incorporation, which shows no difference between ribose or palmitate incorporation, and the use of a palmitate tracer, which demonstrates decreased incorporation across the board in diseased mice (48). This indicates that fatty acids are preferentially being catabolized for oxidative phosphorylation, whereas glutamine is being used as an anabolic substrate, and hints at an alternative metabolism that is specific to pathogenic lymphocytes in GVHD, particularly one that is reliant on lipid oxidation for the vast ATP needs of chronically activated cells. These differences in terms of metabolic demands and reprogramming suggest that metabolic therapy might be able to selectively inhibit activation of the GVHD-inducing cells.

Analysis of competing pathways (Fig. 1) indicates that metabolic therapy specifically targeting fatty acid metabolism (required to meet the increased demand for ATP) with etomoxir would be ideal and could selectively inhibit the persistently activated GVHD-inducing lymphocytes. However, great care must be taken to avoid disturbing the proliferation of nonpathogenic donor cells. In a mouse model of bone marrow allotransplant, proliferating bone marrow cells reconstituting the immune system of a lethally irradiated syngeneic host undergo a dramatically different metabolic program than the pathogenic cells, with the healthy cells relying more on glycolysis than oxidative phosphorylation (47). Small-molecule inhibitors of the  $\text{F}_1\text{F}_0$  ATPase, such as BZ423



**FIGURE 1.** Summary of metabolic pathways vital for T cells responses (black) and drugs that inhibit these pathways (green). The particular condition of autoimmune inflammation the drug has been tested in is in blue.

and LyC-31138, have demonstrated promise as a metabolic therapy for GVHD (47, 48). These drugs prevent the production of ATP, as well as increase the mitochondrial polarization of the pathogenically activated lymphocytes. In allotransplant BMT models of GVHD, these have been shown to rapidly induce apoptosis in the pathogenic cell population and significantly decrease cytokine production, leading to decreased GVHD clinical score and increased survival (47, 48). These ATPase inhibitors act by inducing caspase-regulated apoptosis in the pathogenic cells (47). Importantly, these agents are specific for the pathogenic cells and their rapid requirement for ATP production, and thus do not effect immunological reconstitution of the graft (47). Another therapeutic strategy is targeting fatty acid oxidation with etomoxir, an agent that blocks lipid metabolism at CPT1 (49). After allotransplant, 2 wk of etomoxir treatment was able to decrease clinical GVHD scores from 10 d to a month after the end of treatment. Etomoxir administration was successively able to reduce the proliferation and promote the apoptosis of GVHD-inducing CD8 T cells that have divided numerous times while undivided cells were unaffected (50). This is advantageous, because the highly divided cells were found to be the pathogenic cell population (47). Targeting fatty acid metabolism is a therapeutic strategy that does not impact other cells of the immune system, such as DCs or naive T cells, and does not inhibit graft reconstitution (50).

Despite these impressive results treating GVHD by blocking lipid metabolism, others have found that the pathogenic T cells in GVHD behave metabolically as normally activated T cells. That is, it has more recently been reported that pathogenic T cells in GVHD increase both their glycolytic and oxidative phosphorylation rates, while decreasing their uptake and oxidation of fatty acids (51). Furthermore, inhibition of glycolysis with 3-PO, a specific inhibitor of PFKB3 (52), improved survival and decreased GVHD clinical scores. This improvement was not seen with 2DG, because it was too toxic for the prolonged treatment necessary (51). It remains to be determined whether the differences in observed metabolic phenotypes (reliance on lipid oxidation versus glycolysis) in these studies of GVHD reflect subtle differences between the models with regard to pathogenesis. Most likely both processes will turn out to be playing a role in the GVHD-inducing cells.

### Targeting metabolism in solid organ transplantation

In the case of solid organ transplantation, metabolic therapy has also been employed. However, in this scenario, the metabolic demands of the effector cells promoting graft rejection are somewhat different from those observed in BMT, and thus the antimetabolic targeting strategy is different (53). For solid organ transplant, it appears that there is far less reliance on lipid metabolism for the generation of ATP, and rejecting cells appear to employ aerobic glycolysis (54). This may be due to the fact that, unlike in GVHD, where the donor pathogenic lymphocytes are persistently being activated by host Ag, in the setting of solid organ transplant, the host pathogenic lymphocytes have less frequent encounters with alloantigen. As such, CD4 T cell activation in the setting of solid organ transplant more closely resembles the classical metabolic shift that is seen during the normal activation of lymphocytes (2). To this end, it was found that inhibiting glycolysis with 2DG combined with metformin, an inhibitor of complex I of the electron transport chain (38), can substantially decrease the glycolysis of an activated T cell, and by extension its cytokine production and proliferation (55). When these two drugs are combined with 6-diazo-5-oxo-L-norleucine (DON), a glutamine analogue that broadly inhibits glutamine uptake and metabolism (56–58), and thus its ability to replenish the TCA cycle, it is possible to more completely abrogate the immune response. In the transplant setting, these three drugs can be combined with great effect. Triple therapy with 2DG, metformin, and DON was capable of suppressing the proliferation of pathogenic CD4 and CD8 effector T cells and was able to markedly inhibit completely MHC-mismatched allograft rejection in models of both skin and heart transplantation. Furthermore, due to the fact that Tregs are more reliant on lipid metabolism, the triple therapy inhibited the CD4 effector response, but actually promoted the generation of Ag-specific Tregs (55). That is, the metabolic therapy did not lead to the wholesale inhibition of immune responses but rather, based on differential metabolism, selectively inhibited effector responses while promoting Treg responses. Given these properties, current studies are under way to combine metabolic therapy with tolerance-inducing therapy (e.g., costimulatory blockade) to try to promote long-term tolerance in the absence of long-term immunosuppression.

Furthermore, these studies suggest a potentially broader principle in terms of targeting metabolism as a means of regulating immune responses. It is somewhat striking that, despite the fact that the metabolic inhibitors employed target metabolic pathways found in all cells, the combination therapy in the setting of transplant rejection had a robust therapeutic index (55). That is, although activated effector cells mediating graft rejection were sensitive to metabolic inhibition, resting immune cells and other healthy tissues were relatively unaffected. Indeed, at higher doses, triple therapy might inhibit proliferating gut epithelial cells or result in bone marrow suppression (59, 60). However, for the purpose of preventing allograft rejection, triple metabolic therapy readily inhibited effector cells without significant side effects. These observations point to cellular selectivity based upon demand. That is, relatively nonspecific inhibitors can exert cellular selectivity by differentially affecting cells that necessitate the greatest and/or extraordinary demand for the particular metabolic pathway (Table I).

Manipulating the balance between regulatory and effector T cell metabolism is an effective strategy for the treatment of

autoimmune inflammation. Pyruvate dehydrogenase (PDH) inhibition by PDH kinase (PDHK) promotes the conversion of pyruvate to lactate over the canonical progression of pyruvate to acetyl-CoA (61). When PDHK1 is inhibited by the addition of dichloroacetate (DCA) (62) *in vitro*, it has a specific inhibitory effect on the differentiation and function of Th17 cells, while promoting the generation of T regulatory cells (63). This is likely due to differences in *Pdchk1* expression in the different cell types, because Th17 have higher *Pdchk1* expression levels than Tregs. Therefore, when DCA was used to treat the Th17-driven model of autoimmune inflammation, experimental autoimmune encephalitis, it was found that the inhibition of PDHK significantly decreased disease scores and progression. Disease alleviation was accompanied by an increase in Treg percentage in the draining lymph node and a decrease in activated Th17 percentage recovered (63). PDHK1 also plays a crucial role in macrophage polarization because it is required for M1 macrophage generation and activation in response to the TLR2 agonist PAM, as well as bacterial pathogens that are dependent on TLR2 signaling to induce a response (64). Knockdown of PDHK1 increases the expression of M2 signature genes at early time points after activation and increases the oxidative respiration that preferentially leads to the M2 polarization. Interestingly, etomoxir pretreatment did not have a deleterious effect on M2 polarization as observed 6 h after stimulation, potentially indicating that M2 macrophages do not require fatty acid metabolism until later after activation (64).

*Targeting metabolism in systemic lupus erythematosus*

Another condition of pathogenic T cell activation that has been targeted with metabolic therapy is systemic lupus erythematosus (SLE). Similar to GVHD after BMT, in the case of SLE there is a constant, persistent encounter between the pathogenic lymphocyte (the pathogenesis of SLE is chiefly reliant on CD4 T cells) and its target tissue (65). As a result, pathogenic T cells take on a chronically activated phenotype, and thus have dramatically different metabolic needs than healthy tissue (66). Similar to pathogenic T cells in GVHD, and in contrast with the lymphocytes activated under normal conditions or in the case of solid organ transplant, CD4 T cells in SLE meet their energetic needs mostly through oxidative phosphorylation. Tracer experiments that use <sup>13</sup>C-uniformly-labeled glucose found more oxidation to CO<sub>2</sub> in a NZB/W mouse model of lupus, with no differences in glycolysis or pentose phosphate pathway activity (65). This augmented reliance on oxidative phosphorylation is coupled to increased mitochondrial polarization and mass in the T cells of SLE patients, which is caused in part by decreased mitochondrial autophagy (67). This phenotype can be partially reversed by treatment with 3-PEHPC, a geranylgeranyl transferase inhibitor, which is also sufficient to decrease autoantibody formation and lupus nephritis in both NZB/W and MRL/lpr mouse models of lupus (68).

Further studies have attempted to more fully characterize the metabolism of SLE lymphocytes. Using a triple congenic mouse model of lupus, CD4 T cells were analyzed for metabolic activity *ex vivo* and found them to have increased basal metabolism before the onset of disease, including both

Table 1. Summary of significant works described in this article

Drug	Pathway Targeted	Disease Model	Effect	References
2-Deoxy-D-glucose	Glycolysis (hexokinase)	SLE	Decrease clinical score while leaving normal immune function unaffected (in combination with metformin)	Yin et al. (65, 69)
DON	Glutamine uptake and metabolism	Solid organ transplant	Prolong graft survival (in combination with DON and metformin)	Lee et al. (55)
BZ423/LyC31138	ATP synthase	Solid organ transplant	Prolong graft survival (in combination with 2DG and metformin)	Lee et al. (55)
DCA	Pyruvate branch point (PDHK1)	BMT GVHD	Decrease clinical score while preserving graft reconstitution	Garza et al. (47)Glick et al. (48)
Etomoxir	Lipid metabolism (CPT1α)	Experimental autoimmune encephalitis	Decrease clinical score and pathogenic Th17 formation while promoting Tregs	Gerriets et al. (63)
Metformin	Electron transport chain (complex I)	BMT GVHD	Decrease clinical score while preserving graft reconstitution	Byersdorfer et al. (50)
		SLE	Decrease clinical score while leaving normal immune function unaffected (in combination with 2DG and DON)	Yin et al. (65, 69)
		Solid organ transplant	Prolong graft survival (in combination with 2DG and DON)	Lee et al. (55)

For each drug, its target, the autoimmune inflammation on which the drug was tested, its effect, and the literature reference are listed.

glycolysis, as determined by extracellular acidification rate, and oxidative metabolism, as determined by oxygen consumption rate (69). Predisease cells had decreased spare respiratory capacity as compared with wild type controls, and although they produced ATP at the same rate, predisease cells had a lower ATP charge, indicating increased energy use (69). To gain further insight into the metabolic differences in the lupus mice, extensive gene expression analysis was carried out. As expected, the cells from the lupus mice had higher expression of many genes in the glycolytic pathway, but unexpectedly had an increase in *Cpt1a*, a key regulator of fatty acid oxidation (69). These metabolic analyses, coupled with gene expression differences, open the opportunity for metabolic therapy in the case of SLE.

To capitalize on the metabolic differences between normal and SLE cells, experiments were undertaken to treat the mice with 2-DG and metformin. When these drugs are used to treat the CD4<sup>+</sup> T cells from lupus mice *ex vivo*, they are capable of preventing the production of IFN- $\gamma$ . When given *in vivo*, 2DG and metformin were able to decrease the ECAR and OCR to levels comparable with those of disease-free control animals. Furthermore, they do not affect naive cells or the immune system as a whole, because circulating total Ab levels are unchanged (69). Metabolic therapy is able to prevent disease, because there is a substantially decreased production of autoantibody and formation of pathogenic central memory T cells in the treated mice. These results rely on the synergistic effects of these two drugs, because neither was effective as monotherapy. These results were corroborated in another lupus model (B6.lpr) by the same group, which sought to further refine the possibilities of metabolic intervention. In this model, similar metabolic phenotypes were seen, and the response to metformin and 2-DG treatment was maintained. However, an alternative metabolic therapy, the inhibition of PDHK1 with DCA, was found not to be effective (65).

## Conclusions

The purpose of this brief review is not to provide a comprehensive overview of the emerging field of immunometabolism. Rather, we have detailed a number of instructive examples in the literature where targeting metabolism is able to inhibit autoimmunity and transplant rejection in lieu of traditional immunosuppressive regimens. The dynamic nature of metabolic programming among immune cells is intimately linked to their plasticity and function. We believe that the examples cited mark the beginning of a new approach to treating autoimmune and inflammatory diseases and transplant rejection, that is, targeting metabolism as a means of regulating (not suppressing) immune responses. Indeed, whereas calcineurin inhibitors (cyclosporine and FK506) suppress both effector and regulatory cells, targeting metabolism can simultaneously inhibit effector responses and promote the generation of Tregs (55). In this regard, metabolic therapy might prove to provide a robust platform for promoting tolerance. Furthermore, a common theme emerging from the studies cited is that of cellular selectivity based upon demand, that is, the concept that even a broad inhibitor like 2-DG, which inhibits glycolysis, will selectively inhibit effector cells (that have a markedly enhanced glycolytic demand) yet not adversely affect somatic cells or even T regulatory cells, both of which employ glycolysis but at a much decreased demand when compared with the effector cells.

## Disclosures

J.D.P. is the founder of Dracen Pharmaceuticals. I.A.B. has no financial conflicts of interest.

## References

- Pollizzi, K. N., and J. D. Powell. 2014. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. *Nat. Rev. Immunol.* 14: 435–446.
- Pearce, E. L., M. C. Poffenberger, C. H. Chang, and R. G. Jones. 2013. Fueling immunity: insights into metabolism and lymphocyte function. *Science* 342: 1242–1245.
- Pearce, E. L., and E. J. Pearce. 2013. Metabolic pathways in immune cell activation and quiescence. *Immunity* 38: 633–643.
- Buck, M. D., D. O'Sullivan, and E. L. Pearce. 2015. T cell metabolism drives immunity. *J. Exp. Med.* 212: 1345–1360.
- MacIver, N. J., R. D. Michalek, and J. C. Rathmell. 2013. Metabolic regulation of T lymphocytes. *Annu. Rev. Immunol.* 31: 259–283.
- Warburg, O. 1956. On the origin of cancer cells. *Science* 123: 309–314.
- Vander Heiden, M. G., L. C. Cantley, and C. B. Thompson. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science* 324: 1029–1033.
- Michalek, R. D., V. A. Gerriets, S. R. Jacobs, A. N. Macintyre, N. J. MacIver, E. F. Mason, S. A. Sullivan, A. G. Nichols, and J. C. Rathmell. 2011. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4<sup>+</sup> T cell subsets. *J. Immunol.* 186: 3299–3303.
- Macintyre, A. N., V. A. Gerriets, A. G. Nichols, R. D. Michalek, M. C. Rudolph, D. Deoliveira, S. M. Anderson, E. D. Abel, B. J. Chen, L. P. Hale, and J. C. Rathmell. 2014. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. *Cell Metab.* 20: 61–72.
- Degoffe, G. M., K. N. Pollizzi, A. T. Waickman, E. Heikamp, D. J. Meyers, M. R. Horton, B. Xiao, P. F. Worley, and J. D. Powell. 2011. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. *Nat. Immunol.* 12: 295–303.
- Powell, J. D., K. N. Pollizzi, E. B. Heikamp, and M. R. Horton. 2012. Regulation of immune responses by mTOR. *Annu. Rev. Immunol.* 30: 39–68.
- Pearce, E. L., M. C. Walsh, P. J. Cejas, G. M. Harms, H. Shen, L. S. Wang, R. G. Jones, and Y. Choi. 2009. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. *Nature* 460: 103–107.
- van der Windt, G. J., B. Everts, C. H. Chang, J. D. Curtis, T. C. Freitas, E. Amiel, E. J. Pearce, and E. L. Pearce. 2012. Mitochondrial respiratory capacity is a critical regulator of CD8<sup>+</sup> T cell memory development. *Immunity* 36: 68–78.
- van der Windt, G. J., D. O'Sullivan, B. Everts, S. C. Huang, M. D. Buck, J. D. Curtis, C. Chang, A. M. Smith, T. Ai, B. Faubert, et al. 2013. CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. *Proc. Natl. Acad. Sci. USA* 110: 14336–14341.
- Kelly, B., and L. A. O'Neill. 2015. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. *Cell Res.* 25: 771–784.
- Newsholme, P., R. Curi, S. Gordon, and E. A. Newsholme. 1986. Metabolism of glucose, glutamine, long-chain fatty acids and ketone bodies by murine macrophages. *Biochem. J.* 239: 121–125.
- O'Neill, L. A., and E. J. Pearce. 2016. Immunometabolism governs dendritic cell and macrophage function. *J. Exp. Med.* 213: 15–23.
- Krawczyk, C. M., T. Holowka, J. Sun, J. Blagih, E. Amiel, R. J. DeBerardinis, J. R. Cross, E. Jung, C. B. Thompson, R. G. Jones, and E. J. Pearce. 2010. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. *Blood* 115: 4742–4749.
- Tannahill, G. M., A. M. Curtis, J. Adamik, E. M. Palsson-McDermott, A. F. McGettrick, G. Goel, C. Frezza, N. J. Bernard, B. Kelly, N. H. Foley, et al. 2013. Succinate is an inflammatory signal that induces IL-1 $\beta$  through HIF-1 $\alpha$ . *Nature* 496: 238–242.
- Pearce, E. J., and B. Everts. 2015. Dendritic cell metabolism. *Nat. Rev. Immunol.* 15: 18–29.
- Sbarra, A. J., and M. L. Karnovsky. 1959. The biochemical basis of phagocytosis. I. Metabolic changes during the ingestion of particles by polymorphonuclear leukocytes. *J. Biol. Chem.* 234: 1355–1362.
- Everts, B., E. Amiel, S. C. Huang, A. M. Smith, C. H. Chang, W. Y. Lam, V. Redmann, T. C. Freitas, J. Blagih, G. J. van der Windt, et al. 2014. TLR-driven early glycolytic reprogramming via the kinases TBK1-IRK3 supports the anabolic demands of dendritic cell activation. *Nat. Immunol.* 15: 323–332.
- McGettrick, A. F., and L. A. O'Neill. 2013. How metabolism generates signals during innate immunity and inflammation. *J. Biol. Chem.* 288: 22893–22898.
- Everts, B., E. Amiel, G. J. W. van der Windt, T. C. Freitas, R. Chott, K. E. Yarasheski, E. L. Pearce, and E. J. Pearce. 2012. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. *Blood* 120: 1422–1431.
- Clementi, E., G. C. Brown, M. Feelisch, and S. Moncada. 1998. Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. *Proc. Natl. Acad. Sci. USA* 95: 7631–7636.
- Bauernfeind, F., E. Bartok, A. Rieger, L. Franchi, G. Núñez, and V. Hornung. 2011. Cutting edge: reactive oxygen species inhibitors block priming, but not activation of the NLRP3 inflammasome. *J. Immunol.* 187: 613–617.
- Stephenson, X., M. Foretz, N. Taleux, G. C. van der Zon, E. Sokal, L. Hue, B. Viollet, and B. Guigas. 2011. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. *Diabetologia* 54: 3101–3110.

28. Kelly, B., G. M. Tannahill, M. P. Murphy, and L. A. O'Neill. 2015. Metformin inhibits the production of reactive oxygen species from NADH:ubiquinone oxidoreductase to limit induction of interleukin-1 $\beta$  (IL-1 $\beta$ ) and boosts interleukin-10 (IL-10) in lipopolysaccharide (LPS)-activated macrophages. *J. Biol. Chem.* 290: 20348–20359.
29. Sena, L. A., S. Li, A. Jairaman, M. Prakriya, T. Ezponda, D. A. Hildeman, C. R. Wang, P. T. Schumacker, J. D. Licht, H. Perlman, et al. 2013. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. *Immunity* 38: 225–236.
30. Wellen, K. E., G. Hatzivassiliou, U. M. Sachdeva, T. V. Bui, J. R. Cross, and C. B. Thompson. 2009. ATP-citrate lyase links cellular metabolism to histone acetylation. *Science* 324: 1076–1080.
31. Zhao, S., W. Xu, W. Jiang, W. Yu, Y. Lin, T. Zhang, J. Yao, L. Zhou, Y. Zeng, H. Li, et al. 2010. Regulation of cellular metabolism by protein lysine acetylation. *Science* 327: 1000–1004.
32. Covarrubias, A. J., H. I. Aksoylar, J. Yu, N. W. Snyder, A. J. Worth, S. S. Iyer, J. Wang, I. Ben-Sahra, V. Byles, T. Polynne-Stapornkul, et al. 2016. Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. *eLife* 5: e11612.
33. Infantino, V., P. Convertini, L. Cucci, M. A. Panaro, M. A. Di Noia, R. Calvello, F. Palmieri, and V. Iacobazzi. 2011. The mitochondrial citrate carrier: a new player in inflammation. *Biochem. J.* 438: 433–436.
34. Lampropoulou, V., A. Sergushichev, M. Bambouskova, S. Nair, E. E. Vincent, E. Loginicheva, L. Cervantes-Barragan, X. Ma, S. C. Huang, T. Griss, et al. 2016. Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. *Cell Metab.* 24: 158–166.
35. Cordes, T., M. Wallace, A. Michelucci, A. S. Divakaruni, S. C. Saperkar, C. Sousa, H. Koseki, P. Cabrera, A. N. Murphy, K. Hiller, and C. M. Metallo. 2016. Immunoresponsive gene 1 and itaconate inhibit succinate dehydrogenase to modulate intracellular succinate levels. *J. Biol. Chem.* 291: 14274–14284.
36. Balmer, M. L., E. H. Ma, G. R. Bantug, J. Grähler, S. Pfister, T. Glatter, A. Jauch, S. Dimeloe, E. Slack, P. Dehio, et al. 2016. Memory CD8(+) T cells require increased concentrations of acetate induced by stress for optimal function. *Immunity* 44: 1312–1324.
37. Land, S. C., and A. R. Tee. 2007. Hypoxia-inducible factor 1 $\alpha$  is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. *J. Biol. Chem.* 282: 20534–20543.
38. El-Mir, M. Y., V. Nogueira, E. Fontaine, N. Avéret, M. Rigoulet, and X. Leverve. 2000. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. *J. Biol. Chem.* 275: 223–228.
39. Vats, D., L. Mukundan, J. I. Odegaard, L. Zhang, K. L. Smith, C. R. Morel, R. A. Wagner, D. R. Greaves, P. J. Murray, and A. Chawla. 2006. Oxidative metabolism and PGC-1 $\beta$  attenuate macrophage-mediated inflammation. [Published erratum appears in 2006 Cell Metab. 4: 255.] *Cell Metab.* 4: 13–24.
40. Jha, A. K., S. C. Huang, A. Sergushichev, V. Lampropoulou, Y. Ivanova, E. Loginicheva, K. Chmielewski, K. M. Stewart, J. Ashall, B. Everts, et al. 2015. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. *Immunity* 42: 419–430.
41. Chouchani, E. T., V. R. Pell, E. Gaude, D. Aksentijević, S. Y. Sundier, E. L. Robb, A. Logan, S. M. Nadtochiy, E. N. J. Ord, A. C. Smith, et al. 2014. Isochaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. *Nature* 515: 431–435.
42. He, L., K. J. Weber, and J. D. Schilling. 2016. Glutamine modulates macrophage lipotoxicity. *Nutrients* 8: 215.
43. Luo, W., H. Hu, R. Chang, J. Zhong, M. Knabel, R. O'Meally, R. N. Cole, A. Pandey, and G. L. Semenza. 2011. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. *Cell* 145: 732–744.
44. Anastasiou, D., Y. Yu, W. J. Israelsen, J. K. Jiang, M. B. Boxer, B. S. Hong, W. Tempel, S. Dimov, M. Shen, A. Jha, et al. 2012. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. [Published erratum appears in 2012 Nat. Chem. Biol. 8: 1008.] *Nat. Chem. Biol.* 8: 839–847.
45. Palsson-McDermott, E. M., A. M. Curtis, G. Goel, M. A. Lauterbach, F. J. Sheedy, L. E. Gleeson, M. W. van den Bosch, S. R. Quinn, R. Domingo-Fernandez, D. G. Johnston, et al. 2015. Pyruvate kinase M2 regulates Hif-1 $\alpha$  activity and IL-1 $\beta$  induction and is a critical determinant of the warburg effect in LPS-activated macrophages. [Published erratum appears in 2015 Cell Metab. 21: 347.] *Cell Metab.* 21: 65–80.
46. Wang, R., C. P. Dillon, L. Z. Shi, S. Milasta, R. Carter, D. Finkelstein, L. L. McCormick, P. Fitzgerald, H. Chi, J. Munger, and D. R. Green. 2011. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. *Immunity* 35: 871–882.
47. Gatza, E., D. R. Wahl, A. W. Opipari, T. B. Sundberg, P. Reddy, C. Liu, G. D. Glick, and J. L. Ferrara. 2011. Manipulating the bioenergetics of alloreactive T cells causes their selective apoptosis and arrests graft-versus-host disease. *Sci. Transl. Med.* 3: 67ra8.
48. Glick, G. D., R. Rossignol, C. A. Lyssiotis, D. Wahl, C. Lesch, B. Sanchez, X. Liu, L. Y. Hao, C. Taylor, A. Hurd, et al. 2014. Anaplerotic metabolism of alloreactive T cells provides a metabolic approach to treat graft-versus-host disease. *J. Pharmacol. Exp. Ther.* 351: 298–307.
49. Lopaschuk, G. D., S. R. Wall, P. M. Olley, and N. J. Davies. 1988. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. *Circ. Res.* 63: 1036–1043.
50. Byersdorfer, C. A., V. Tkachev, A. W. Opipari, S. Goodell, J. Swanson, S. Sandquist, G. D. Glick, and J. L. Ferrara. 2013. Effector T cells require fatty acid metabolism during murine graft-versus-host disease. *Blood* 122: 3230–3237.
51. Nguyen, H. D., S. Chatterjee, K. M. Haarberg, Y. Wu, D. Bastian, J. Heinrichs, J. Fu, A. Daenthanasanmak, S. Schutt, S. Shrestha, et al. 2016. Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation. *J. Clin. Invest.* 126: 1337–1352.
52. Schoors, S., K. De Bock, A. R. Cantelmo, M. Georgiadou, B. Ghesquière, S. Cauwenberghs, A. Kuchnio, B. W. Wong, A. Quaegebeur, J. Goveia, et al. 2014. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. *Cell Metab.* 19: 37–48.
53. Lo, Y. C., C. F. Lee, and J. D. Powell. 2014. Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection. *Curr. Opin. Organ Transplant.* 19: 363–371.
54. Priyadarshini, B., and L. A. Turka. 2015. T-cell energy metabolism as a controller of cell fate in transplantation. *Curr. Opin. Organ Transplant.* 20: 21–28.
55. Lee, C. F., Y. C. Lo, C. H. Cheng, G. J. Furtmüller, B. Oh, V. Andrade-Oliveira, A. G. Thomas, C. E. Bowman, B. S. Slusher, M. J. Wolfgang, et al. 2015. Preventing allograft rejection by targeting immune metabolism. *Cell Rep.* 13: 760–770.
56. Shapiro, R. A., V. M. Clark, and N. P. Curthoys. 1979. Inactivation of rat renal phosphate-dependent glutaminase with 6-diazo-5-oxo-L-norleucine. Evidence for interaction at the glutamine binding site. *J. Biol. Chem.* 254: 2835–2838.
57. Ortlund, E., M. W. Lacombe, K. Lewinski, and L. Lebiada. 2000. Reactions of *Pseudomonas* 7A glutaminase-asparaginase with diazo analogues of glutamine and asparagine result in unexpected covalent inhibitions and suggests an unusual catalytic triad Thr-Tyr-Glu. *Biochemistry* 39: 1199–1204.
58. Thangavelu, K., Q. Y. Chong, B. C. Low, and J. Sivaraman. 2014. Structural basis for the active site inhibition mechanism of human kidney-type glutaminase (KGA). *Sci. Rep.* 4: 3827.
59. Cooney, D. A., H. N. Jayaram, H. A. Milman, E. R. Homan, R. Pittillo, R. I. Geran, J. Ryan, and R. J. Rosenbluth. 1976. DON, CONV and DONV-III. Pharmacologic and toxicologic studies. *Biochem. Pharmacol.* 25: 1859–1870.
60. Sklaroff, R. B., E. S. Casper, G. B. Magill, and C. W. Young. 1980. Phase I study of 6-diazo-5-oxo-L-norleucine (DON). *Cancer Treat. Rep.* 64: 1247–1251.
61. Kaplon, J., L. Zheng, K. Meissl, B. Chaneton, V. A. Selivanov, G. Mackay, S. H. van der Burg, E. M. Verdegaal, M. Cascante, T. Shlomi, et al. 2013. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. *Nature* 498: 109–112.
62. Stacpoole, P. W. 1989. The pharmacology of dichloroacetate. *Metabolism* 38: 1124–1144.
63. Gerriets, V. A., R. J. Kishton, A. G. Nichols, A. N. Macintyre, M. Inoue, O. Ilkayeva, P. S. Winter, X. Liu, B. Priyadarshini, M. E. Slawinska, et al. 2015. Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. *J. Clin. Invest.* 125: 194–207.
64. Tan, Z., N. Xie, H. Cui, D. R. Moellering, E. Abraham, V. J. Thannickal, and G. Liu. 2015. Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via regulating glucose metabolism. *J. Immunol.* 194: 6082–6089.
65. Yin, Y., S. C. Choi, Z. Xu, L. Zeumer, N. Kanda, B. P. Croker, and L. Morel. 2016. Glucose oxidation is critical for CD4+ T cell activation in a mouse model of systemic lupus erythematosus. *J. Immunol.* 196: 80–90.
66. Wahl, D. R., B. Petersen, R. Warner, B. C. Richardson, G. D. Glick, and A. W. Opipari. 2010. Characterization of the metabolic phenotype of chronically activated lymphocytes. *Lupus* 19: 1492–1501.
67. Caza, T. N., G. Talaber, and A. Perl. 2012. Metabolic regulation of organelle homeostasis in lupus T cells. *Clin. Immunol.* 144: 200–213.
68. Caza, T. N., D. R. Fernandez, G. Talaber, Z. Oaks, M. Haas, M. P. Madaio, Z. W. Lai, G. Miklossy, R. R. Singh, D. M. Chudakov, et al. 2014. HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. *Ann. Rheum. Dis.* 73: 1888–1897.
69. Yin, Y., S. C. Choi, Z. Xu, D. J. Perry, H. Seay, B. P. Croker, E. S. Sobel, T. M. Brusko, and L. Morel. 2015. Normalization of CD4+ T cell metabolism reverses lupus. *Sci. Transl. Med.* 7: 274ra18.